Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

VivoSim Labs, Inc. - Common Stock (NQ:VIVS)

0.2483 +0.0213 (+9.38%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,461,199
Open 0.2284
Bid (Size) 0.2405 (1,000)
Ask (Size) 0.2550 (1,000)
Prev. Close 0.2270
Today's Range 0.2240 - 0.2640
52wk Range 0.2167 - 4.114
Shares Outstanding 8,716,953
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Greenland Stocks in Focus: GLND, GRML, CRML Lead the Watchlist More Names Inside
Via AB Newswire
Topics Government
News headline image
VivoSim Labs Inc. (NASDAQ: VIVS) Takes Aim at Pharma’s 92% Drug-Failure Problem
Via AB Newswire
Topics Animal Testing

Performance

YTD
-86.8%
-86.8%
1 Month
-15.0%
-15.0%
3 Month
-78.0%
-78.0%
6 Month
-85.0%
-85.0%
1 Year
-93.3%
-93.3%

More News

Read More
News headline image
High-Impact Stocks DRK, VIVS, AEMD, GMG in the News
Via AB Newswire
Topics Artificial Intelligence Energy
News headline image
VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
Catch the Danger, Spare the Cure: Why VivoSim’s (NASDAQ: VIVS) 90%/95% Toxicity Results Matter
Via AB Newswire
Topics Artificial Intelligence
News headline image
VivoSim Labs (NASDAQ: VIVS): Predicting Drug Toxicity Before Human Clinical Trials
Via AB Newswire
News headline image
VivoSim Labs (NASDAQ: VIVS) Opens New Pharma Opportunity
Via AB Newswire
News headline image
Microcaps GPRO, FLYE, HKPD, VIVS to Watch Now
Via AB Newswire
Topics Artificial Intelligence Supply Chain
News headline image
VivoSim Labs to Add Rat Liver Model to NAMkind Platform
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
IGC Pharma (NYSE: IGC) Target Raised on Alzheimer’s 2027 Outlook
Via AB Newswire
Topics Artificial Intelligence
News headline image
VivoSim Labs (NASDAQ: VIVS): 10,000 Compounds to 1 Drug with AI-Powered 3D Human Toxicology
Via AB Newswire
Topics Artificial Intelligence
News headline image
Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks Now
Via AB Newswire
Topics Artificial Intelligence
News headline image
VivoSim Labs (NASDAQ: VIVS) Research Report Highlights AI-Powered Drug Toxicity Platform, FDA NAM Momentum
Via AB Newswire
Topics Animal Testing Artificial Intelligence
News headline image
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum
Via AB Newswire
Topics Animal Testing Artificial Intelligence
News headline image
VivoSim Labs (NASDAQ: VIVS) Emerges in Drug Toxicity Market as Revenue Growth Guidance Tops 500% – Plus More In Focus
Via AB Newswire
Topics Animal Testing Artificial Intelligence
News headline image
Oversold Stocks TOON, RMCF, PRSO, OFAL Offer Opportunity – See Why Inside
Via AB Newswire
Topics Artificial Intelligence
News headline image
VivoSim Provides Financial and Listing Compliance Update
From VivoSim Labs, Inc.
Via GlobeNewswire
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
MissionIRNewsBreaks – VivoSim Labs, Inc. (NASDAQ: VIVS) Announces $4 Million Private Placement
Via Investor Brand Network
Topics Animal Testing
News headline image
VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services
From VivoSim Labs, Inc.
Via GlobeNewswire
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
Thursday's session: top gainers and losers ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027
From VivoSim Labs, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is VivoSim Labs, Inc. - Common Stock publicly traded?
Yes, VivoSim Labs, Inc. - Common Stock is publicly traded.
What exchange does VivoSim Labs, Inc. - Common Stock trade on?
VivoSim Labs, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for VivoSim Labs, Inc. - Common Stock?
The ticker symbol for VivoSim Labs, Inc. - Common Stock is VIVS on the Nasdaq Stock Market
What is the current price of VivoSim Labs, Inc. - Common Stock?
The current price of VivoSim Labs, Inc. - Common Stock is 0.2483
When was VivoSim Labs, Inc. - Common Stock last traded?
The last trade of VivoSim Labs, Inc. - Common Stock was at 09/21/26 04:00 PM ET
What is the market capitalization of VivoSim Labs, Inc. - Common Stock?
The market capitalization of VivoSim Labs, Inc. - Common Stock is 2.16M
How many shares of VivoSim Labs, Inc. - Common Stock are outstanding?
VivoSim Labs, Inc. - Common Stock has 2M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.